Barclays PLC Boosts Holdings in Wave Life Sciences Ltd. (NASDAQ:WVE)

Barclays PLC grew its position in shares of Wave Life Sciences Ltd. (NASDAQ:WVE - Free Report) by 22.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 195,553 shares of the company's stock after acquiring an additional 36,312 shares during the quarter. Barclays PLC owned about 0.13% of Wave Life Sciences worth $2,418,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. KBC Group NV acquired a new stake in Wave Life Sciences in the fourth quarter valued at approximately $67,000. Summit Investment Advisors Inc. increased its stake in Wave Life Sciences by 31.5% during the 4th quarter. Summit Investment Advisors Inc. now owns 9,642 shares of the company's stock worth $119,000 after buying an additional 2,308 shares during the period. Westwood Wealth Management acquired a new position in Wave Life Sciences in the 4th quarter worth $124,000. Raymond James Financial Inc. purchased a new position in Wave Life Sciences in the 4th quarter valued at about $157,000. Finally, Victory Capital Management Inc. increased its position in shares of Wave Life Sciences by 16.6% during the fourth quarter. Victory Capital Management Inc. now owns 14,546 shares of the company's stock worth $180,000 after acquiring an additional 2,073 shares during the last quarter. Hedge funds and other institutional investors own 89.73% of the company's stock.

Insider Activity at Wave Life Sciences

In other news, Director Christian O. Henry sold 10,500 shares of the company's stock in a transaction on Thursday, March 20th. The shares were sold at an average price of $9.77, for a total value of $102,585.00. Following the completion of the sale, the director now owns 16,115 shares in the company, valued at $157,443.55. This represents a 39.45 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Paul Bolno sold 169,025 shares of Wave Life Sciences stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $9.57, for a total transaction of $1,617,569.25. Following the transaction, the chief executive officer now directly owns 338,351 shares in the company, valued at approximately $3,238,019.07. This represents a 33.31 % decrease in their position. The disclosure for this sale can be found here. 29.10% of the stock is currently owned by company insiders.

Wave Life Sciences Price Performance

NASDAQ WVE traded up $0.16 during trading on Friday, reaching $8.10. 3,725,765 shares of the company's stock were exchanged, compared to its average volume of 1,241,252. Wave Life Sciences Ltd. has a fifty-two week low of $4.25 and a fifty-two week high of $16.74. The stock has a market capitalization of $1.25 billion, a P/E ratio of -7.30 and a beta of -0.91. The business has a 50 day moving average price of $8.16 and a 200-day moving average price of $11.44.

Wave Life Sciences (NASDAQ:WVE - Get Free Report) last released its quarterly earnings results on Tuesday, March 4th. The company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.34. The business had revenue of $83.75 million during the quarter, compared to the consensus estimate of $25.60 million. Wave Life Sciences had a negative return on equity of 280.57% and a negative net margin of 66.50%. On average, analysts forecast that Wave Life Sciences Ltd. will post -1.14 earnings per share for the current year.

Analyst Ratings Changes

WVE has been the subject of several research analyst reports. Cantor Fitzgerald assumed coverage on shares of Wave Life Sciences in a research report on Tuesday, April 29th. They issued an "overweight" rating and a $10.00 target price for the company. Jefferies Financial Group started coverage on Wave Life Sciences in a research note on Tuesday, February 25th. They set a "buy" rating and a $26.00 price objective on the stock. Wedbush started coverage on shares of Wave Life Sciences in a report on Tuesday, April 8th. They set an "outperform" rating and a $18.00 target price on the stock. StockNews.com raised shares of Wave Life Sciences from a "sell" rating to a "hold" rating in a research report on Saturday, March 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $22.00 target price on shares of Wave Life Sciences in a report on Wednesday, March 26th. Two analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Wave Life Sciences presently has a consensus rating of "Moderate Buy" and an average price target of $21.17.

Wave Life Sciences Profile

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders.